New Psychedelic-Like Molecules May Treat Depression Without Causing Hallucinations
Scientists at the University of California, Davis have developed a new class of psychedelic-inspired compounds that may help treat depression and other mental health disorders without causing hallucinations. The molecules target the same key serotonin receptor activated by classic psychedelics but did not produce typical hallucinogenic-like effects in animal experiments.
The study, published in the Journal of the American Chemical Society, focused on the serotonin 5-HT2A receptor, which has long been associated with mood regulation and brain plasticity. Many psychedelic substances activate this receptor and are currently being investigated as potential treatments for depression, PTSD, and addiction. However, their powerful perceptual effects create legal, safety, and accessibility challenges.
Designing Non-Hallucinogenic Compounds
The UC Davis research team used a light-driven chemistry technique to transform common amino acids—the building blocks of proteins—into entirely new molecules. By combining amino acids with tryptamine and exposing the mixtures to ultraviolet light, the scientists generated hundreds of molecular structures not naturally found in biology.
Researchers then used computational modeling to predict how strongly the compounds would bind to the 5-HT2A receptor. From roughly 100 promising candidates, the team selected five compounds for detailed laboratory testing, evaluating how effectively each activated serotonin-related signaling pathways involved in brain cell growth and plasticity.
The compounds produced activity levels ranging from 61 percent to 93 percent of the receptor’s maximum possible response. One molecule, called D5, stood out as a full agonist, meaning it was capable of triggering the receptor’s strongest theoretical response—similar to classic psychedelics such as LSD or psilocybin in laboratory systems.
Unexpected Results In Animal Tests
Because D5 activated the same receptor targeted by psychedelic drugs, researchers expected it to produce head-twitch responses in mice, a commonly used marker associated with hallucinogenic-like activity. Surprisingly, this effect did not occur, even at doses where the compound strongly activated the receptor.
Rather than inducing psychedelic-like behavior, D5 appeared to suppress it. This finding suggests the compound may alter serotonin signaling in a way that separates therapeutic effects from hallucinations. Researchers now suspect that other serotonin receptors or downstream signaling pathways may influence the final outcome.
The team says the results point toward the possibility of designing drugs that enhance brain plasticity and improve mood without significantly altering perception or consciousness. Such medications could potentially be easier to regulate and administer outside specialized psychedelic treatment clinics.
Implications For Future Mental Health Treatments
Current psychedelic-assisted therapies often require extensive supervision, long treatment sessions, and tightly controlled clinical environments because of their intense psychological effects. A non-hallucinogenic alternative offering similar therapeutic benefits could significantly simplify treatment and make it more accessible for patients.
The UC Davis study also introduces an entirely new chemical scaffold for psychiatric drug discovery. Much of psychedelic research has traditionally focused on modifying known molecular families such as tryptamines and phenethylamines, while completely new structural frameworks remain relatively uncommon.
Going forward, the researchers plan to investigate exactly how D5 and related compounds interact with different serotonin receptors and signaling networks. Understanding why these molecules activate 5-HT2A without triggering hallucinogenic-like behavior could help scientists develop next-generation treatments for depression, PTSD, and related disorders.
The project involved collaborators from UC Davis, HepatoChem Inc., the Medical College of Wisconsin, and UC San Diego. Funding was provided by the National Institutes of Health and the Source Research Foundation.
The findings add to a growing wave of research aimed at creating safer and more targeted psychedelic-inspired therapies that preserve potential mental health benefits while minimizing disruptive side effects.
